Heron Patrick J Insider Trading -- Recent SEC Form 4 Transactions

Heron Patrick J (CIK 1365617) reported 28 SEC Form 4 insider transactions across 4 companies over the past 18 months (most recent 2026-06-09). Recent activity: Buy ARQT (5,778 shares), Buy MIRM (159,277 shares), Buy MIRM (131,425 shares), Buy MBX (666,666 shares), Sell HLVX (8.5M shares). Source: SEC Form 4.

DateCompanyRoleTypeSharesValue
2026-06-09Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy5,778$0
2026-01-27Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy159,277$0
2026-01-27Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy131,425$9.0M
2025-09-30MBX Biosciences, Inc. (MBX)DirectorBuy666,666$12.0M
2025-09-17HilleVax, Inc. (HLVX)DirectorSell8.5M$16.6M
2025-09-17HilleVax, Inc. (HLVX)DirectorSell17,199$33,538
2025-06-25HilleVax, Inc. (HLVX)DirectorBuy17,199$0
2025-06-17Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy2,646$34,610
2025-06-16Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy7,609$0
2025-06-06Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy1,890$25,175
2025-06-06Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy378$5,069
2025-06-02Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy5,703$0
2025-05-23Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy2,520$34,423
2025-05-23Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy2,520$34,398
2025-05-19Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy2,520$34,322
2025-05-15Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy2,374$32,666
2025-05-15Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy6,300$86,688
2025-05-13Arcutis Biotherapeutics, Inc. (ARQT)DirectorBuy6,300$85,680
2025-03-18Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy528$23,290
2025-03-18Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy21$923
2025-03-12Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy758$32,336
2025-03-12Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy577$25,024
2025-03-12Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy963$42,151
2025-03-10Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy1,335$58,593
2025-03-10Mirum Pharmaceuticals, Inc. (MIRM)DirectorBuy580$25,062

Source: SEC Form 4 filings · as of 2026-06-09